


# Towards personalized medicine in gastric, pancreatic and liver cancer. From « omics » research to treatment

Michel Ducreux  
Gustave Roussy  
Villejuif

# → Disclosure

- Participation to advisory boards:
  - Celgene
  - Sanofi
  - Merck Serono
  - Roche
  - Novartis
  - AMGEN
- Lectures in symposium
  - Celgene
  - Novartis
  - Merck Serono
  - Roche
- Research funding
  - Roche
  - Celgene

# BCLC staging and treatment strategy



RFA = radiofrequency ablation;

PEI = percutaneous ethanol injection.


Llovet JM, et al. J Natl Cancer Inst 2008;100:698–711.

# → Treatment of HCC after failure to Sorafenib

	Mode of action	PFS	OS	Subgroup
Brivanib	VEGF and FGF inhibitor	4.2 vs 2.7* (TTP)	9.4 vs 8.2	AFP<200 ng/mL
Everolimus	mTOR inhibitor	3.0 vs 2.6 (TTP)	7.6 vs 7.3	No
Axitinib	VEGFR, PDFR, cKit inhibitor	3.6 vs 1.9*	12.7 vs 9.7	Asian patients
Ramucirumab	Anti-VEGFR2 antibody	2.8 vs 2.1*	9.2 vs 7.6	AFP>400 ng/mL


# → Overall survival: very similar results

## Overall Survival of ITT Population



Abbreviations: CI=confidence interval; HR=hazard ratio; ITT=Intent to treat; OS=overall survival.


## Overall Survival: All Randomised Patients (N=202)




\*1-sided stratified log-rank test

# → As a conclusion for HCC

- There is something but we are unable to demonstrate
- Because different diseases:




# Gastric cancer: HER2 story





# → RAINBOW : Overall survival

**OS median: 9.63 months RAM+PTX vs 7.36 months PTX  
(HR : 0.807 [95% IC : 0.678-0.962] p=0.0169)**




# → Molecular subtypes of gastric cancer



# → Pancreatic cancer

Gem ± Marimastat (Bramhall, BJC 2002)	5.5	5.5	NS
Gem ± Tifarbinib (Van Cutsem, JCO 2004)	6.0	6.4	NS
Gem ± Erlotinib (Moore, JCO 2007)	5.9	6.4	.03
Gem ± Bevacizumab (Kindler, JCO 2010)	6.1	5.8	NS
Gem ± Cetuximab (Philip, JCO 2010)	5.9	6.4	NS
Gem ± GV1001 (Buanes, ASCO 2009)	7.3	5.9	NS
Gem – Erlotinib ± Beva (Van Cutsem, JCO 2009)	6.0	7.1	NS
Gem ± Axitinib (Kindler, Lancet Oncol 2011)	7.4	8.2	NS
Gem ± Aflibercept (Rougier EJC 2013)	7.8	6.5	NS

# → Pancreatic cancer Folfirinox: Overall Survival




# → Work has been done...


A



B



C



# → Genomics and GI cancer?

